Compare Recursion Pharmaceuticals Inc (RXRX) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Sony Group Corp — how do they compare? Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B), while Sony Group Corp trades at $24.04 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 64× Recursion Pharmaceuticals Inc's market cap, and Sony Group Corp pays a 0.66% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Sony Group Corp for 96 Days on average.
| RXRX | SONY | |
|---|---|---|
Market Cap | $2.14B | $136.87B |
Volume | 30,789,535 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $6.79 | $30.26 |
52-Week Low | $2.84 | $19.32 |
Typical Hold Time | 22 Days | 96 Days |
Enterprise Value | $1.66B | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Sony trades at $24.05, up 2.25% with mixed technical signals and neutral analyst sentiment. The company reported strong Q2 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent news highlights Sony's content strength and legal actions against AI companies for copyright infringement.
Sony presents a mixed investment case with strong cash flow generation and content portfolio offset by near-term profitability concerns. The stock's valuation appears reasonable with P/E of 20.34, but investors should monitor the company's ability to improve margins amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
